AcelRX post-op pain treatment meets late-stage study goal

by admin on May 21, 2013

(Reuters) – AcelRX Pharmaceuticals Inc said its experimental treatment for post-operative pain met its main goal in a late-stage trial of patients who had undergone knee or hip replacement surgery, sending its shares up 15 percent. AcelRX said its Sufentanil NanoTab PCA System showed a decrease in pain intensity, compared with a placebo, as measured on a clinical scale 48 hours after surgery. In …

View full post on pain – Yahoo! News Search Results

Previous post:

Next post: